Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.86 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL29203651 | 0.97 | KIF11 (0.83) | KIF11EPHX2CA1CA2TRPV1 | |
| Hydrochloric Acid SCHEMBL27956160 | 0.97 | KIF11 (0.83) | KIF11EPHX2CA1CA2TRPV1 | |
| Hydrochloric Acid SCHEMBL27956162 | 0.97 | KIF11 (0.83) | KIF11EPHX2CA1CA2TRPV1 | |
| SCHEMBL5428301 | 0.93 | KIF11 (1.00) | KIF11EPHX2CA1CA2 | |
| SCHEMBL19822993 | 0.87 | KIF11 (0.68) | KIF11EPHX2CA1CA2TRPV1 | |
| SCHEMBL14311924 | 0.83 | KIF11 (0.63) | KIF11EPHX2CA1CA2TRPV1 | |
| SCHEMBL22298750 | 0.82 | KIF11 (0.61) | KIF11CA1CA2ALDH1A1 | |
| SCHEMBL22198310 | 0.82 | KIF11 (0.61) | KIF11EPHX2TRPV1NPC1RAB9A | |
| SCHEMBL12024617 | 0.82 | KIF11 (0.61) | KIF11EPHX2CA1CA2TRPV1 | |
| SCHEMBL22270553 | 0.81 | KIF11 (0.70) | KIF11EPHX2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277693-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2024-08-22 | — | — | US | claimed |
| CN-117886718-B | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-05-24 | — | — | CN | claimed |
| EP-4363404-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | Active Biotech AB (SE) | 2024-05-08 | — | — | EP | claimed |
| CN-117886718-A | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-04-16 | — | — | CN | claimed |
| CN-117500790-A | Pharmaceutical product containing taquinimod and method for evaluating purity of said product | 活跃生物技术有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-110698432-B | Benzyl piperazine compound, preparation method thereof and application thereof in antivirus | 中国医学科学院医药生物技术研究所 | 2023-02-03 | — | — | CN | claimed |
| WO-2023275248-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2023-01-05 | — | — | WO | claimed |
| CN-112209847-B | Method for preparing amide compound under catalysis of ionic liquid in high-pressure environment | 烟台大学 | 2022-12-23 | — | — | CN | claimed |
| CN-112209847-A | Method for preparing amide compound under catalysis of ionic liquid in high-pressure environment | 烟台大学 | 2021-01-12 | — | — | CN | claimed |
| CN-110128340-B | Synthesis method of quinolinone compounds | 绍兴文理学院 | 2020-10-30 | — | — | CN | claimed |
| US-9216956-B2 | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | ACTIVE BIOTECH AB (SE) | 2015-12-22 | — | — | US | claimed |
| CN-103796654-A | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | ACTIVE BIOTECH AB | 2014-05-14 | — | — | CN | claimed |
| EP-2723340-A1 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | Active Biotech AB (SE) | 2014-04-30 | — | — | EP | claimed |
| US-20140112946-A1 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | ACTIVE BIOTECH AB (SE) | 2014-04-24 | — | — | US | claimed |
| WO-2012175541-A1 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | ACTIVE BIOTECH AB (SE) | 2012-12-27 | — | — | WO | claimed |
| EP-2537517-A1 | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | Active Biotech AB (SE) | 2012-12-26 | — | — | EP | claimed |
| WO-2011058577-A1 | PROCESS FOR SYNTHESIZING POLYHALOGENATED PERHALOALKYLANILINE COMPOUNDS | GHARDA KEKI HORMUSJI (IN) | 2011-05-19 | — | — | WO | claimed |
| US-7943605-B2 | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses | UCB PHARMA S.A. (BE) | 2011-05-17 | — | — | US | claimed |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | COASY, FURIN, PEPD | KIF11 3429/4885EPHX2 1624/4885CA1 3317/4885 |
| US-20140112946-A1 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | H1-5, MALT1, H1-4 | KIF11 3733/4885EPHX2 3176/4885CA1 2733/4885 |
| US-20240277693-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | TPMT, TLR7, MYD88 | KIF11 1870/4885EPHX2 3424/4885CA1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.